C2N Diagnostics, LLC (C2N), a speciality diagnostics company with a vision to bring Clarity Through Innovation, is reaching additional global healthcare providers eager to use its PrecivityAD2 blood test to help diagnose Alzheimer’s disease. The PrecivityAD2 blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, for patients being evaluated for cognitive complaints through a simple, non-invasive blood test.
The company has secured partnerships with six new clinical reference laboratories and distributors, expanding its footprint to over seven additional countries.
C2N’s new partnerships are with:
Accuserv Diagnostic Centre (Philippines)
Archerfish Precision Diagnostics (Singapore and other Southeast Asian markets; further details are available through its news release)
Codex Genetics (Hong Kong)
Dr. Dangs Lab (India)
Medical Link (Israel)
Milenia Labs (Costa Rica and Mexico)
C2N also maintains partnerships with leading labs around the world, including Grupo Fleury, Healius, Mayo Clinic Laboratories, and Unilabs, along with a research collaboration with Mediford.
Dr. Joel Braunstein, CEO of C2N Diagnostics, says, “These new international partnerships are intended to broaden access to C2N’s innovative Precivity portfolio of blood tests in markets facing growing healthcare pressures, given ageing populations, a lack of dementia specialists, and inadequate PET infrastructure. These partnerships are a testament to the science and research that have already assisted healthcare providers in delivering a clear picture of Alzheimer’s disease pathology to patients and their families in many countries. The growing burden of Alzheimer’s disease requires the healthcare system to explore new ways to offer less costly and more accessible diagnostic testing, and we look forward to helping more patients around the world receive an early and accurate diagnosis.”
The PrecivityAD2 blood test involves a simple blood draw from the patient and is intended for patients aged 55 and older with signs or symptoms of cognitive impairment who are undergoing evaluation for Alzheimer's disease or other causes of cognitive decline.
